Contrasting of PhaseBio Pharmaceuticals Inc. (PHAS) and Zealand Pharma A/S (NASDAQ:ZEAL)

This is therefore a contrasting of the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation in PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and Zealand Pharma A/S (NASDAQ:ZEAL). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PhaseBio Pharmaceuticals Inc. N/A 179.54 21.51M -1.02 0.00 Zealand Pharma A/S N/A 0.00 N/A 3.00 4.40 Table 1 highlights PhaseBio Pharmaceuticals Inc. and Zealand Pharma A/S’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Institutional & Insider Ownership

Roughly 52.36% of PhaseBio Pharmaceuticals Inc. shares are owned by institutional investors while 9.72% of Zealand Pharma A/S are owned by institutional investors. Insiders owned roughly 0.1% of PhaseBio Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) PhaseBio Pharmaceuticals Inc. 28.77% -28.18% 0% 0% 0% -26.6% Zealand Pharma A/S -2.22% -3.57% -23.18% -13.76% -1.71% -2.79% For the past year PhaseBio Pharmaceuticals Inc.’s stock price has bigger decline than Zealand Pharma A/S.


Zealand Pharma A/S beats on 4 of the 6 factors PhaseBio Pharmaceuticals Inc.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company’s product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Tags:, ,